MedPath

Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing

Phase 4
Conditions
Sleep Disordered Breathing
Registration Number
NCT00299910
Lead Sponsor
Soroka University Medical Center
Brief Summary

This study will assess in a double blind placebo controlled fashion the effects of a 12 week course of oral montelukast/placebo on polysomnographic and radiological findings and will characterize the systemic (serum,urine) and local (upper airway collected biological samples) inflammatory response in children (2-10 years of age) with sleep disordered breathing, fittingthe inclusion and exclusion criteria.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria

2-10 years old

1<AHI<8 measured in an overnight PSG

Read More
Exclusion Criteria

Asthma Previous use or allergy to montelukast Use of antibiotics in the previous 3 weeks Use of corticosteroids in the previous 3 months Craniofacial dysmorphism Genetic or metabolic defined illnesses Adenotonsillectomy or adenoidectomy in the past

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pediatric Sleep Center, Soroka University Medical Center

🇮🇱

Beer-Sheva, Israel

© Copyright 2025. All Rights Reserved by MedPath